利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

238 条记录 (耗时 0.022 秒)

    NOVEL OMEGA-3 AND OMEGA-6 FATTY ACID COMPOSITIONS AND USES THEREOF
    8.
    发明公开
    NOVEL OMEGA-3 AND OMEGA-6 FATTY ACID COMPOSITIONS AND USES THEREOF 审中-公开
    新型OMEGA-3和OMEGA-6脂肪酸组合物及其用途

    公开(公告)号：EP2627326A2

    公开(公告)日：2013-08-21

    申请号：EP11776135.3

    申请日：2011-10-12

    申请人： Vifor SA

    发明人： TERREAUX, Christian ,  HOMBERGER, Eleonora ,  KRIWET, Burkhard ,  BARRAGAN PEREZ, Eduardo

    IPC分类号： A61K31/202 ,  A61K31/4458 ,  A61K33/26 ,  A61K33/30 ,  A61P25/28

    CPC分类号： A61K31/202 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/4458 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K31/714 ,  A61K33/26 ,  A61K33/30 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/156 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1874 ,  A23V2250/2132 ,  A23V2250/70

    摘要： The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCI, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine. The present application also relates to the method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising administering an effective amount of a composition comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCI, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.

    摘要翻译： 本申请涉及用于在对象中治疗和/或预防精神和行为障碍和/或改善精神健康和认知功能的方法中的组合物，其包含：a）二十二碳六烯酸（DHA）和/或其药学上可接受的衍生物 和/或其前体; b）二十碳五烯酸（EPA）和/或其药学上可接受的衍生物和/或前体; c）γ-亚麻酸（GLA）和/或其药学上可接受的衍生物和/或前体; 和至少一种选自盐酸哌甲酯，阿托西汀，苯丙胺，γ-羟基丁酸酯，右旋安非他命，西布曲明，亚甲基二氧基甲基苯丙胺和/或选自氟西汀，舍曲林，帕罗西汀，氟胺，柠檬醛，文拉法辛，安非他酮，奈法唑酮和抗焦虑药的抗焦虑化合物中的精神兴奋剂化合物 米氮平。 本申请还涉及治疗和/或预防个体的精神和行为障碍和/或改善精神健康和认知功能的方法，其包括给予有效量的组合物，所述组合物包含：a）二十二碳六烯酸（DHA）和/ 或其药学上可接受的衍生物和/或前体; b）二十碳五烯酸（EPA）和/或其药学上可接受的衍生物和/或前体; c）γ-亚麻酸（GLA）和/或其药学上可接受的衍生物和/或前体; 和至少一种选自盐酸哌甲酯，阿托西汀，苯丙胺，γ-羟基丁酸酯，右旋安非他命，西布曲明，亚甲基二氧基甲基苯丙胺和/或选自氟西汀，舍曲林，帕罗西汀，氟胺，柠檬醛，文拉法辛，安非他酮，奈法唑酮和抗焦虑药的抗焦虑化合物中的精神兴奋剂化合物 米氮平。